#
Title
1

Suzanne E. Schindler, MD, PhD - AAIC 2026: Advancing Alzheimer’s Disease Detection, Diagnosis, and Treatment Through New Evidence

2

Oluwatosin Goje, MD, MSCR, FACOG - Vulvovaginal Candidiasis Uncovered: Navigating Accurate Diagnosis and Optimal Treatment in the Age of Resistance

3

Vallerie V. McLaughlin, MD - Optimizing PAH Outcomes in Primary Care: Shifting the Paradigm Toward Early Intervention and Escalation

4

Michael Heinrich, MD - Redefining Interprofessional Care Paradigms in Gastrointestinal Stromal Tumors (GIST): Clinical "Take-Homes" for Established and Rapidly Emerging Evidence on TKIs Across the Disease Continuum

5

Jonathan W. Goldman, MD - Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities

6

Paul E. Sax, MD / Eileen Scully, MD, PhD - Contemporary HIV Management: Therapeutic Advances and Real-World Approaches to Patient Care

7

Christie M. Ballantyne, MD, MNLA, FACP, FACC, Jessica M. Peña, MD, MPH, FACC, FNLA, FAHA - Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management

8

Philip J. Mease, MD, MACR - Breaking the Burden of Systemic Lupus Erythematosus: Patient Testimonials and Interprofessional Perspectives on New Developments With CAR-T Cell Therapy

9

Maximilian Johannes Hochmair, MD / Zosia Piotrowska, MD, MHS - New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance

10

Ticiana Leal, MD - The Expanding Immunotherapy Frontier in NSCLC: From Established ICI-Based Approaches to the Next Wave of Innovation

11

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, FCAHS - Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum

12

Javier Morales, MD, FACP, FACE - Bridging Knowledge to Action: Translating Evidence Into Practice for Type 2 Diabetes Management

13

Scott Kopetz, MD, PhD, FACP - Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment

14

Luke Maese, DO, Rachel Rau, MD - ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients

15

Jaume Capdevila, MD, PhD - Propelling Modern Interventions in Neuroendocrine Carcinoma: Multidisciplinary Principles to Effectively Implement Emerging DLL3-Directed BiTE Therapy in Community Settings

16

Anita Afzali, MD, MPH, MHCM, FACG, AGAF / Jessica R. Allegretti, MD, MPH, FACG, AGAF / Millie D. Long, MD, MPH - At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition

17

Anna Chodos, MD, MPH - Getting Ahead of Cognitive Decline—Applying Patient-Centered Strategies to Assess and Reduce Dementia Risk in Primary Care: An AI-Guided Case Simulation Activity

18

Ibrahim Aldoss, MD - Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice

19

Gerald Appel, MD / Ellie Kelepouris, MD, FACP, FAHA - IgA Nephropathy Evolved: Redefining Standards of Care Through Innovation and Evidence

20

Professor Frank Jessen, MD - AD/PD 2026: Advancing Alzheimer’s Disease Detection, Diagnosis, and Treatment Through New Evidence

21

Sarah Cuddy, MD / Vasvi Singh, MD, FACC, FASNC, FSCCT - Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice

22

Milind Desai, MD, MBA / Anjali Tiku Owens, MD - Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM?

23

Amber Luong, MD, PhD, FACS - Blocking Type 2 Inflammation in CRSwNP With Targeted Biologic Therapy: Personalizing Care to Achieve Improved Patient Outcomes

24

Krish Patel, MD / Nirav Shah, MD, MS - Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy and CAR-T and Revisiting the Role of Transplant

25

Pooja Singhal, MD AGAF, FACG - First Move Matters: Playing to Win in EoE – From Emergency Department Recognition to Continued Care Strategies

26

Hans Lee, MD - Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma

27

Komal Jhaveri, MD, FACP - Navigating Multifactorial Clinical Decisions in HR+ EBC and MBC: A Case-Based, Algorithmic Guide

28

Kathleen N. Moore, MD, MS - A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

29

Andrea Necchi, MD - Maximizing Therapeutic Innovations in Bladder Cancer: Expert Strategies for Comprehensive Care Across Disease Stages

30

Sheela Rao, MBBS, MD, FRCP - Strengthening the Immunotherapy Paradigm in Advanced SCAC: Established and Emerging Roles of Immune-Based Platforms Across Lines of Therapy

31

Courtney R. Arn, APRN-CNP / Kimberly Halla, MSN, FNP-C - Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches

32

Brooke Looney, PharmD, CSP, Izabela Mazur, PharmD, BCOP - Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists

33

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smarter Approaches for Diagnosing HoFH